Cargando…

Intermediate- vs. Standard-Dose Prophylactic Anticoagulation in Patients With COVID-19 Admitted in Medical Ward: A Propensity Score-Matched Cohort Study

Background: Microthrombosis and large-vessel thrombosis are the main triggers of COVID-19 worsening. The optimal anticoagulant regimen in COVID-19 patients hospitalized in medical wards remains unknown. Objectives: To evaluate the effects of intermediate-dose vs. standard-dose prophylactic anticoagu...

Descripción completa

Detalles Bibliográficos
Autores principales: Smadja, David M., Bonnet, Guillaume, Gendron, Nicolas, Weizman, Orianne, Khider, Lina, Trimaille, Antonin, Mirault, Tristan, Fauvel, Charles, Diehl, Jean-Luc, Mika, Delphine, Philippe, Aurelien, Pezel, Théo, Goudot, Guillaume, Sutter, Willy, Planquette, Benjamin, Waldmann, Victor, Sanchez, Olivier, Cohen, Ariel, Chocron, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553987/
https://www.ncbi.nlm.nih.gov/pubmed/34722585
http://dx.doi.org/10.3389/fmed.2021.747527
_version_ 1784591694465859584
author Smadja, David M.
Bonnet, Guillaume
Gendron, Nicolas
Weizman, Orianne
Khider, Lina
Trimaille, Antonin
Mirault, Tristan
Fauvel, Charles
Diehl, Jean-Luc
Mika, Delphine
Philippe, Aurelien
Pezel, Théo
Goudot, Guillaume
Sutter, Willy
Planquette, Benjamin
Waldmann, Victor
Sanchez, Olivier
Cohen, Ariel
Chocron, Richard
author_facet Smadja, David M.
Bonnet, Guillaume
Gendron, Nicolas
Weizman, Orianne
Khider, Lina
Trimaille, Antonin
Mirault, Tristan
Fauvel, Charles
Diehl, Jean-Luc
Mika, Delphine
Philippe, Aurelien
Pezel, Théo
Goudot, Guillaume
Sutter, Willy
Planquette, Benjamin
Waldmann, Victor
Sanchez, Olivier
Cohen, Ariel
Chocron, Richard
author_sort Smadja, David M.
collection PubMed
description Background: Microthrombosis and large-vessel thrombosis are the main triggers of COVID-19 worsening. The optimal anticoagulant regimen in COVID-19 patients hospitalized in medical wards remains unknown. Objectives: To evaluate the effects of intermediate-dose vs. standard-dose prophylactic anticoagulation (AC) among patients with COVID-19 hospitalized in medical wards. Methods and results: We used a large French multicentric retrospective study enrolling 2,878 COVID-19 patients hospitalized in medical wards. After exclusion of patients who had an AC treatment before hospitalization, we generated a propensity-score-matched cohort of patients who were treated with intermediate-dose or standard-dose prophylactic AC between February 26 and April 20, 2020 (intermediate-dose, n = 261; standard-dose prophylactic anticoagulation, n = 763). The primary outcome of the study was in-hospital mortality; this occurred in 23 of 261 (8.8%) patients in the intermediate-dose group and 74 of 783 (9.4%) patients in the standard-dose prophylactic AC group (p = 0.85); while time to death was also the same in both the treatment groups (11.5 and 11.6 days, respectively, p = 0.17). We did not observe any difference regarding venous and arterial thrombotic events between the intermediate dose and standard dose, respectively (venous thrombotic events: 2.3 vs. 2.4%, p=0.99; arterial thrombotic events: 2.7 vs. 1.2%, p = 0.25). The 30-day Kaplan–Meier curves for in-hospital mortality demonstrate no statistically significant difference in in-hospital mortality (HR: 0.99 (0.63–1.60); p = 0.99). Moreover, we found that no particular subgroup was associated with a significant reduction in in-hospital mortality. Conclusion: Among COVID-19 patients hospitalized in medical wards, intermediate-dose prophylactic AC compared with standard-dose prophylactic AC did not result in a significant difference in in-hospital mortality.
format Online
Article
Text
id pubmed-8553987
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85539872021-10-30 Intermediate- vs. Standard-Dose Prophylactic Anticoagulation in Patients With COVID-19 Admitted in Medical Ward: A Propensity Score-Matched Cohort Study Smadja, David M. Bonnet, Guillaume Gendron, Nicolas Weizman, Orianne Khider, Lina Trimaille, Antonin Mirault, Tristan Fauvel, Charles Diehl, Jean-Luc Mika, Delphine Philippe, Aurelien Pezel, Théo Goudot, Guillaume Sutter, Willy Planquette, Benjamin Waldmann, Victor Sanchez, Olivier Cohen, Ariel Chocron, Richard Front Med (Lausanne) Medicine Background: Microthrombosis and large-vessel thrombosis are the main triggers of COVID-19 worsening. The optimal anticoagulant regimen in COVID-19 patients hospitalized in medical wards remains unknown. Objectives: To evaluate the effects of intermediate-dose vs. standard-dose prophylactic anticoagulation (AC) among patients with COVID-19 hospitalized in medical wards. Methods and results: We used a large French multicentric retrospective study enrolling 2,878 COVID-19 patients hospitalized in medical wards. After exclusion of patients who had an AC treatment before hospitalization, we generated a propensity-score-matched cohort of patients who were treated with intermediate-dose or standard-dose prophylactic AC between February 26 and April 20, 2020 (intermediate-dose, n = 261; standard-dose prophylactic anticoagulation, n = 763). The primary outcome of the study was in-hospital mortality; this occurred in 23 of 261 (8.8%) patients in the intermediate-dose group and 74 of 783 (9.4%) patients in the standard-dose prophylactic AC group (p = 0.85); while time to death was also the same in both the treatment groups (11.5 and 11.6 days, respectively, p = 0.17). We did not observe any difference regarding venous and arterial thrombotic events between the intermediate dose and standard dose, respectively (venous thrombotic events: 2.3 vs. 2.4%, p=0.99; arterial thrombotic events: 2.7 vs. 1.2%, p = 0.25). The 30-day Kaplan–Meier curves for in-hospital mortality demonstrate no statistically significant difference in in-hospital mortality (HR: 0.99 (0.63–1.60); p = 0.99). Moreover, we found that no particular subgroup was associated with a significant reduction in in-hospital mortality. Conclusion: Among COVID-19 patients hospitalized in medical wards, intermediate-dose prophylactic AC compared with standard-dose prophylactic AC did not result in a significant difference in in-hospital mortality. Frontiers Media S.A. 2021-10-15 /pmc/articles/PMC8553987/ /pubmed/34722585 http://dx.doi.org/10.3389/fmed.2021.747527 Text en Copyright © 2021 Smadja, Bonnet, Gendron, Weizman, Khider, Trimaille, Mirault, Fauvel, Diehl, Mika, Philippe, Pezel, Goudot, Sutter, Planquette, Waldmann, Sanchez, Cohen and Chocron. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Smadja, David M.
Bonnet, Guillaume
Gendron, Nicolas
Weizman, Orianne
Khider, Lina
Trimaille, Antonin
Mirault, Tristan
Fauvel, Charles
Diehl, Jean-Luc
Mika, Delphine
Philippe, Aurelien
Pezel, Théo
Goudot, Guillaume
Sutter, Willy
Planquette, Benjamin
Waldmann, Victor
Sanchez, Olivier
Cohen, Ariel
Chocron, Richard
Intermediate- vs. Standard-Dose Prophylactic Anticoagulation in Patients With COVID-19 Admitted in Medical Ward: A Propensity Score-Matched Cohort Study
title Intermediate- vs. Standard-Dose Prophylactic Anticoagulation in Patients With COVID-19 Admitted in Medical Ward: A Propensity Score-Matched Cohort Study
title_full Intermediate- vs. Standard-Dose Prophylactic Anticoagulation in Patients With COVID-19 Admitted in Medical Ward: A Propensity Score-Matched Cohort Study
title_fullStr Intermediate- vs. Standard-Dose Prophylactic Anticoagulation in Patients With COVID-19 Admitted in Medical Ward: A Propensity Score-Matched Cohort Study
title_full_unstemmed Intermediate- vs. Standard-Dose Prophylactic Anticoagulation in Patients With COVID-19 Admitted in Medical Ward: A Propensity Score-Matched Cohort Study
title_short Intermediate- vs. Standard-Dose Prophylactic Anticoagulation in Patients With COVID-19 Admitted in Medical Ward: A Propensity Score-Matched Cohort Study
title_sort intermediate- vs. standard-dose prophylactic anticoagulation in patients with covid-19 admitted in medical ward: a propensity score-matched cohort study
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553987/
https://www.ncbi.nlm.nih.gov/pubmed/34722585
http://dx.doi.org/10.3389/fmed.2021.747527
work_keys_str_mv AT smadjadavidm intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy
AT bonnetguillaume intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy
AT gendronnicolas intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy
AT weizmanorianne intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy
AT khiderlina intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy
AT trimailleantonin intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy
AT miraulttristan intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy
AT fauvelcharles intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy
AT diehljeanluc intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy
AT mikadelphine intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy
AT philippeaurelien intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy
AT pezeltheo intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy
AT goudotguillaume intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy
AT sutterwilly intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy
AT planquettebenjamin intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy
AT waldmannvictor intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy
AT sanchezolivier intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy
AT cohenariel intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy
AT chocronrichard intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy